MoonLake Immunotherapeutics
MLTX
$17.80
-$0.20-1.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -77.04% | -91.13% | -160.62% | -221.44% | -256.99% |
| Total Depreciation and Amortization | 114.84% | 88.88% | 61.36% | 77.52% | 106.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 292.57% | 85.70% | 26.41% | 72.34% | 508.54% |
| Change in Net Operating Assets | 790.75% | 625.32% | 353.43% | 120.74% | 86.36% |
| Cash from Operations | -60.36% | -68.12% | -130.79% | -158.28% | -187.01% |
| Capital Expenditure | 100.00% | 93.27% | 66.43% | 30.93% | 30.93% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 222.16% | 199.00% | 44.83% | 132.15% | -64.35% |
| Cash from Investing | 221.82% | 198.73% | 46.02% | 131.86% | -63.70% |
| Total Debt Issued | -66.49% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 23,014.62% | 38.26% | -99.13% | -99.59% | -99.94% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 102.13% | 102.13% |
| Cash from Financing | 40.93% | 184.53% | -7.32% | -7.48% | -86.16% |
| Foreign Exchange rate Adjustments | 12,000.00% | 766.41% | 723.43% | 1,320.47% | 79.17% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 114.41% | 156.91% | -143.35% | 77.29% | -145.77% |